ProfileGDS5678 / 1427097_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 94% 94% 94% 91% 94% 95% 95% 94% 93% 94% 95% 95% 95% 95% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 18.1614594
GSM967853U87-EV human glioblastoma xenograft - Control 28.2047694
GSM967854U87-EV human glioblastoma xenograft - Control 38.2039394
GSM967855U87-EV human glioblastoma xenograft - Control 47.5928291
GSM967856U87-EV human glioblastoma xenograft - Control 58.2021694
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 18.2383195
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 28.0907295
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.1873294
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.8134993
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 18.2099894
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 28.2893395
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 38.3792195
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 48.4299595
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 58.2752395